The Missing Link in Cardiometabolic Care: Who Is Coordinating the Whole Patient?
The 2026 CKM guideline recognizes what many patients already experience: heart, kidney, metabolic, and weight-related conditions cannot be managed effectively in silos.
A patient with obesity, diabetes, hypertension, and chronic kidney disease may see a primary care clinician, a cardiologist, an endocrinologist, a nephrologist, and several other members of the care team. Each of them may provide excellent care. Yet one basic question often goes unanswered:
Who is looking across the entire picture?
That question matters because cardiovascular, kidney, and metabolic diseases do not behave like separate conditions. They interact, accelerate one another, and increasingly share the same treatments. In 2026, major professional societies formally recognized this reality.
What Changed in the 2026 CKM Guideline
The 2026 AHA/ACC/ADA/ASN guideline brings conditions long treated in separate lanes into a single clinical framework: cardiovascular-kidney-metabolic (CKM) syndrome. CKM describes the interconnected relationships among metabolic risk factors — including obesity and type 2 diabetes — chronic kidney disease, and cardiovascular disease. Parallel guidance from the American Society of Nephrology frames the same syndrome from the kidney perspective, reinforcing that these conditions belong in one clinical conversation rather than several.
Within this framework, obesity is not simply an isolated diagnosis. It can be an important driver of CKM risk and progression.
The heart, kidneys, metabolism, and weight are connected. Our model of care should be connected too.
The guideline's organizational recommendation is especially important. For adults with stage 2–4 CKM syndrome who have at least two of diabetes, CKD, and/or cardiovascular disease, it recommends interdisciplinary care teams with a CKM care coordination point person to facilitate multisystem care, including lifestyle intervention and optimization of guideline-directed medical therapy. This is a Class 1, Level B-R recommendation.
The guideline also recommends addressing adverse social determinants of health as part of interdisciplinary CKM care, including involving community health workers, social workers, and patient navigators when appropriate.
The message is increasingly clear: coordination is no longer an optional extra. It is becoming part of evidence-based cardiometabolic care.
Why Fragmented Care Matters
Guidelines can identify the need for coordination, but most healthcare systems were never designed around it.
Cardiometabolic care sits at the intersection of several specialties whose responsibilities naturally overlap. Primary care clinicians, cardiologists, endocrinologists, nephrologists, pharmacists, and other team members may all address blood pressure, cholesterol, glucose, weight, kidney function, and cardiovascular risk.
That overlap is not inherently a problem. The problem arises when several people are responsible, but no one is clearly responsible for connecting the entire picture. When ownership of individual decisions becomes unclear, treatment can stall, because each clinician may reasonably assume someone else is addressing the issue.
Shared responsibility without clear coordination can become no responsibility at all.
One of the most visible consequences is the underuse of therapies already known to prevent cardiovascular events, slow kidney disease progression, and improve outcomes. In a large 2025 health-system analysis, 82.5% of patients with type 2 diabetes had a cardiovascular or kidney indication for an SGLT2 inhibitor and/or GLP-1 receptor agonist, yet only 33.2% had an active prescription.
These gaps are not evenly distributed. Among Medicare beneficiaries with type 2 diabetes and newly diagnosed ASCVD or heart failure, adoption of SGLT2 inhibitors and GLP-1 receptor agonists was lower among Black patients and among people living in more socioeconomically deprived communities.
This is not a story of bad clinicians. It is a story of a healthcare system that was never designed for diseases that refuse to stay inside one specialty's lane.
Fragmentation itself may carry measurable risk. In a Danish nationwide cohort, greater healthcare fragmentation was independently associated with more potentially inappropriate medication use and higher mortality. Conversely, among more than 312,000 patients with type 2 diabetes, greater team-based continuity of care was associated with progressively lower cardiovascular risk.
Continuity is not simply a convenience. It can function as a clinical intervention.
What Coordinated CKM Care Looks Like
The solution is not to create another silo. It is to build an interdisciplinary model with someone clearly responsible for coordinating the whole picture. The 2026 guideline describes adaptable models that can operate in person, virtually, or through a combination of both.
At the center is the CKM care coordination point person. That role may include:
comprehensive medication review and reconciliation
supporting initiation and titration of evidence-based therapies
helping patients understand and access medications
facilitating lifestyle change
coordinating communication across clinicians
helping patients navigate a complex healthcare system
The evidence supporting structured coordination is growing. In COORDINATE-Diabetes, a cluster-randomized trial across U.S. cardiology clinics, a multifaceted intervention increased prescription of all three recommended evidence-based therapy groups from 14.5% with usual care to 37.9%. Longer-term, team-based studies point in the same direction: multidisciplinary, multifactorial care can improve cardiovascular risk factors, glycemic control, and blood pressure, and, in selected populations, long-term outcomes.
But coordination by itself is not enough.
The goal is not more communication. The goal is communication that leads to action.
A coordinator empowered to reconcile medications, facilitate initiation and titration, identify treatment gaps, and close the loop is far more likely to influence outcomes than one limited mainly to relaying messages.
In practice, coordinated CKM care means doing several things consistently: identifying a coordination point person, clarifying who manages each major risk factor, using evidence-based treatment pathways, finding eligible-but-untreated patients through EHR or registry tools, incorporating pharmacists and other team members, and deliberately protecting continuity and equity.
How Technology Can Help
Technology can make coordinated CKM care more scalable when it supports — rather than replaces — clinical relationships.
Telehealth is particularly well suited to CKM care because these conditions require longitudinal attention. Blood pressure, glucose, weight, symptoms, medications, physical activity, and adherence all evolve between office visits, and remote care can help clinicians see those changes earlier. Connected devices and structured follow-up can support more timely medication adjustment.
Well-designed electronic records can improve clinician-to-clinician communication, embed evidence-based pathways, and track important metrics longitudinally. Remote specialty support can extend expertise beyond traditional referral models, particularly where access to subspecialists is limited. Clinical decision support may also help identify patients who qualify for therapies but have not yet received them.
Technology should be the connective tissue of coordinated care — not the center of care.
The evidence should also temper enthusiasm. A 2025 scoping review found encouraging results for telehealth, particularly for glycemic control and self-management, but evidence for broader cardiovascular-risk improvement remained heterogeneous. Digital care can also widen disparities if we ignore broadband access, digital literacy, language, affordability, and patients' ability to use connected devices.
The right question, then, is not simply, "Can this visit be virtual?" It is: What combination of technology, human support, and in-person care gives this patient the best chance of succeeding?
What This Means for the Future of Cardiometabolic Care
The emerging CKM framework asks us to think differently about chronic disease. Obesity, diabetes, hypertension, dyslipidemia, kidney disease, and cardiovascular risk are not simply separate diagnoses that happen to occur in the same person. They are often interconnected expressions of the same underlying cardiometabolic process.
Better care requires someone to see the whole patient, not just the diagnosis in front of them. That means identifying risk early, and using predicted risk and expected treatment benefit — rather than each risk factor in isolation — to guide what we do about it. It means making sure evidence-based therapies are actually implemented. It means coordinating care across conditions and specialties. And it means following patients longitudinally rather than treating each visit as an isolated event.
The 2026 CKM guideline gives this coordinating role a name: the CKM care coordination point person. More importantly, it gives healthcare systems a challenge:
Organize care around the patient — not around the specialty.
Technology can help make that possible. Telehealth, remote monitoring, shared data, clinical decision support, and better communication systems can make longitudinal care easier to deliver. But technology remains a tool. The relationship, judgment, accountability, and coordination remain human.
At WellifyCare Medical, this integrated view of cardiometabolic health is central to how we think about prevention and chronic disease management. Our goal is simple: understand the whole risk picture, intervene earlier, coordinate care thoughtfully, and help patients protect their health across the years — not simply manage one number or one diagnosis at a time.
The science has connected the heart, kidneys, metabolism, and weight. Our models of care now need to catch up.
Dereje Tefera Siyum, MD, MSHI, DABOM
Founder & Physician, WellifyCare Medical
Internal Medicine | Obesity Medicine | Clinical Informatics
This article is for general educational purposes and is not a substitute for individualized medical advice. Talk with your clinician about what is right for you.
